video
Webinar: Neuroinflammation discovery assays
Join Malvern Panalytical for a 15-minute webinar to learn about ex vivo inflammasome slice assays for neuroinflammation discovery.
List view / Grid view
Hit-to-Lead
article
Rapidly transitioning from in silico hits to leads on ‘undruggable’ pain targets
Opioid addiction is an ongoing crisis in the US. Researchers have identified a key regulator that shapes analgesic and aversive outputs of kappa opioid receptor signalling, finding lead inhibitors of this previously ‘undruggable’ target class – the Regulators of G protein Signalling (RGS proteins) – to help re-establish non-addictive kappa…
video
Webinar: Immunotherapy discovery & development
Discover key target cells for immunotherapy, how cells and processes can be assessed in vitro and approaches for selecting the most appropriate assay.
article
Drug Target Review – Issue 4 2022
A new Drug Target Review issue is now ready to download! This issue features articles which explore how artificial intelligence can enhance screening and ways to find new hits through simultaneous orthogonal screens. Also included are articles on CRISPR, immuno-oncology and RSV vaccines.
video
Webinar: Making API candidate selection more productive
Discover everything pharmaceutical scientists need to know about solid form characterisation, starting with API selection.
video
Webinar: Top tips for successful particle size analysis
Discover how Malvern Panalytical’s combination of analytical instrumentation and research services can take particle size analysis to the next level.
whitepaper
Guide: Understanding an API and all its forms with XRPD
This Malvern Panalytical guide explores the use of Xray powder diffraction (XRPD) as a powerful tool to develop and improve pharmaceutical formulation.
whitepaper
Whitepaper: Unique solutions for drug discovery and development
Looking for solutions to resolve your unique challenges? We offer several customized products and services to move your discovery forward.
webinar
Translating complex, high-parameter immune data from clinical samples into actionable disease insights
1 November 2022 | By Standard BioTools
Watch our on-demand webinar to hear about advances toward precision medicine through the use of cutting-edge methods and analysing critical patient immune data in response to therapies and disease progression.
news
Pre-clinical trials show drug inhibits inflammasome in COVID-19 cases
Anti-inflammatory effects of niclosamide, observed in a new pre-clinical study, were due to inhibition of the inflammasome, a protein complex presented in the interior of defence cells.
news
Discovery of two drugs could lead to earlier pancreatic cancer treatment
In pre-clinical studies, the University of Florida has identified two drugs that reverse ADM, a process that precedes pancreatic cancer.
article
Drug Target Review’s highlights from ELRIG Drug Discovery 2022
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
news
New drug has potential to turn COVID-19 virus against itself
The Scripps Research team showed that a variation of an already FDA-approved therapeutic for neurological disease can block COVID-19 infection in animals.
news
Scientists discover multiple pathways of the 5HT2a receptor activated by psychedelics
The new LSD-like compounds activated the 5HT2a receptor, a receptor stimulated by serotonin, without causing hallucinations.
news
6 reasons to attend Drug Discovery 2022… especially if you are an early career professional
Europe’s largest meeting for life sciences professionals is just around the corner – be a part of it. This year, Drug Discovery 2022 is coming to the ever-buzzing ExCel centre in London from 4-5 October and will focus on ‘driving the next life sciences revolution’ as we build new momentum…
